Enzychem Lifesciences Corporation (183490.KQ)
KRW 1147.0
(-1.12%)
KRW 1147.0
(-1.12%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.02 Billion KRW | 50.0% |
| 2022 | 683.32 Million KRW | -78.48% |
| 2021 | 3.17 Billion KRW | -91.45% |
| 2020 | 37.11 Billion KRW | 12355.83% |
| 2019 | 298.01 Million KRW | -0.66% |
| 2018 | 300 Million KRW | -76.92% |
| 2017 | 1.3 Billion KRW | -51.85% |
| 2016 | 2.7 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.01 Billion KRW | -0.73% |
| 2024 Q2 | 410 Million KRW | -59.71% |
| 2023 Q1 | 389.16 Million KRW | -43.05% |
| 2023 FY | 1.02 Billion KRW | 50.0% |
| 2023 Q3 | 1.03 Billion KRW | -0.72% |
| 2023 Q2 | 1.04 Billion KRW | 167.24% |
| 2023 Q4 | 1.02 Billion KRW | -0.73% |
| 2022 Q2 | 1.74 Billion KRW | -29.15% |
| 2022 Q1 | 2.45 Billion KRW | -22.57% |
| 2022 Q4 | 683.32 Million KRW | -33.33% |
| 2022 FY | 683.32 Million KRW | -78.48% |
| 2022 Q3 | 1.02 Billion KRW | -41.15% |
| 2021 Q4 | 3.17 Billion KRW | -92.37% |
| 2021 Q2 | 39.95 Billion KRW | 3.15% |
| 2021 Q3 | 41.59 Billion KRW | 4.09% |
| 2021 Q1 | 38.73 Billion KRW | 3.48% |
| 2021 FY | 3.17 Billion KRW | -91.45% |
| 2020 Q4 | 37.43 Billion KRW | 436.78% |
| 2020 FY | 37.11 Billion KRW | 12355.83% |
| 2020 Q1 | 298.14 Million KRW | 0.04% |
| 2020 Q3 | 6.97 Billion KRW | 60.46% |
| 2020 Q2 | 4.34 Billion KRW | 1357.81% |
| 2019 Q4 | 298.01 Million KRW | -14.02% |
| 2019 FY | 298.01 Million KRW | -0.66% |
| 2019 Q1 | 400.47 Million KRW | 33.49% |
| 2019 Q3 | 346.59 Million KRW | -8.88% |
| 2019 Q2 | 380.37 Million KRW | -5.02% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 FY | 300 Million KRW | -76.92% |
| 2018 Q2 | 600 Million KRW | 0.0% |
| 2018 Q3 | 450 Million KRW | -25.0% |
| 2018 Q4 | 300 Million KRW | -33.33% |
| 2017 FY | 1.3 Billion KRW | -51.85% |
| 2017 Q4 | 1.3 Billion KRW | 0.0% |
| 2016 FY | 2.7 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 988.75 Million KRW | -3.666% |
| CMG Pharmaceutical Co., Ltd. | 19.06 Billion KRW | 94.623% |
| Celltrion Pharm, Inc. | 4.33 Billion KRW | 76.346% |
| Huons Global Co., Ltd. | 66.94 Billion KRW | 98.469% |
| DongKook Pharmaceutical Co., Ltd. | 18.74 Billion KRW | 94.533% |
| Humedix Co., Ltd. | 1.75 Billion KRW | 41.606% |
| Boditech Med Inc. | 2.09 Billion KRW | 51.189% |
| EuBiologics Co., Ltd. | 2.8 Billion KRW | 63.393% |
| FutureChem Co.,Ltd | 2.61 Billion KRW | 60.875% |
| Huons Co., Ltd. | 58.35 Billion KRW | 98.243% |
| BNC Korea Co., Ltd. | 301.69 Million KRW | -239.752% |
| AptaBio Therapeutics Inc. | 13.56 Billion KRW | 92.446% |